Hold Rating on Immunic Amidst Ongoing Vido Clinical Trials and Financial Outlook
Immunic, Inc. (NASDAQ:IMUX) Q1 2024 Earnings Call Transcript
Immunic | 10-Q: Quarterly report
Immunic Says It Bolstered Balance Sheet Through Three-tranche Private Placement Totaling Up To $240M, Extending Cash Runway Into Q3 2025, Based On Initial $80M Tranche
Immunic Says It Bolstered Balance Sheet Through Three-tranche Private Placement Totaling Up To $240M, Extending Cash Runway Into Q3 2025, Based On Initial $80M Tranche
Immunic: Q1 Earnings Snapshot
Immunic Q1 EPS $(0.30) Misses $(0.26) Estimate, Cash And Equivalents As Of March 31, 2024 Were $97.3M
Immunic (NASDAQ:IMUX) reported quarterly losses of $(0.30) per share which missed the analyst consensus estimate of $(0.26) by 15.38 percent. This is a 48.28 percent increase over losses of $(0.58) pe
Express News | Immunic Inc - Expects to Be Able to Fund Its Operations Into Q3 of 2025.
Express News | Immunic Q1 Operating Expenses USD 23.881 Million
Express News | Immunic Q1 Income From Operations USD -23.881 Million
Express News | Immunic Q1 Basic EPS USD -0.3
Express News | Immunic Q1 Net Income USD -29.584 Million
Press Release: Immunic, Inc. Reports First Quarter 2024 Financial Results and Provides Corporate Update
Immunic, Inc. Reports First Quarter 2024 Financial Results and Provides Corporate Update PR Newswire NEW YORK, May 8, 2024 -- Substantially Bolstered Balance Sheet Through a Three-Tranche Private P
Immunic 1Q Loss $29.6M >IMUX
Immunic 1Q Loss $29.6M >IMUX
Immunic 1Q Loss/Shr 30c >IMUX
Immunic 1Q Loss/Shr 30c >IMUX
Immunic, Inc. Reports First Quarter 2024 Financial Results and Provides Corporate Update
Immunic Advances 'potentially Groundbreaking' MS Therapy Vidofludimus Calcium During Q1 | NASDAQ:IMUX
Immunic Advances 'potentially Groundbreaking' MS Therapy Vidofludimus Calcium | NASDAQ:IMUX
Immunic to Participate in Investor and Scientific Conferences in May
NEW YORK, May 6, 2024 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory an
Immunic Phase 2 EMPhASIS Trial Data Highlighted in Peer-reviewed Neurology Journal
Express News | Immunic, Inc. to Announce Financial Results for the First Quarter Ended March 31, 2024, and Provide Corporate Update
No Data